Forefront Analytics’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$557K Sell
6,158
-416
-6% -$34.8K 0.61% 17
2026
Q1
$526K Buy
6,574
+461
+8% +$38K 0.48% 16
2025
Q4
$521K Buy
6,113
+1,621
+36% +$133K 0.46% 20
2025
Q3
$349K Buy
4,492
+47
+1% +$3.67K 0.34% 28
2025
Q2
$348K Sell
4,445
-526
-11% -$39.2K 0.39% 27
2025
Q1
$360K Buy
4,971
+1,745
+54% +$125K 0.41% 23
2024
Q4
$239K Buy
3,226
+84
+3% +$5.88K 0.11% 51
2024
Q3
$207K Buy
+3,142
New +$228K 0.1% 57

Other funds holding EW

Forefront Analytics's EW Position: Q2 2026 in Review

Forefront Analytics reduced its Edwards Lifesciences (EW) stake by 6.3% in Q2 2026, selling an estimated $34.8K and leaving 6,158 shares worth $557K. The position accounts for 0.61% of the portfolio, ranked #17.

Forefront Analytics first reported a position in EW in Q3 2024 and has held it in 8 quarters since. 1,332 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Forefront Analytics held 6,158 shares of Edwards Lifesciences worth $557K as of Q2 2026.
  • Forefront Analytics sold 416 Edwards Lifesciences shares in Q2 2026, an estimated $34.8K.
  • Edwards Lifesciences made up 0.61% of Forefront Analytics's portfolio in Q2 2026, its #17 holding.
  • Forefront Analytics first reported a position in Edwards Lifesciences in Q3 2024 and has held it in 8 quarters since.
  • 1,332 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Forefront Analytics's 13F filing for Q2 2026, filed 13 Aug 2026.